On May 26, 2021, the US Food and Drug Administration approved the COVID-19 monoclonal antibody (mAb) treatment called sotrovimab made by GlaxoSmithKline LLC, making it available for emergency use during the COVID-19 pandemic.
as of April 5, 2022, the U.S. Food and Drug Administration has revoked approval of the COVID-19 monoclonal antibody (mAb) treatment called sotrovimab in all U.S. states and territories. This is due to an increase in COVID-19 cases caused by the Omicron BA. sub-variant and data showing that sotrovimab is unlikely to be as effective against it.
Like many other viruses, the SARS-CoV-2 virus that causes COVID-19 is evolving and changing over time. This means that what made the virus susceptible to certain treatments or vaccines may change. As COVID-19 becomes an endemic disease, meaning that it is still present but not causing significant disruption in our daily lives, the virus will continue to change and new variants will arise.
In the future, new variants may arise that may once again be treatable with sotrovimab.